Orca-T expanded access for advanced blood cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This program offers the experimental cell therapy Orca-T to people with advanced blood cancers when the standard approved version isn't available due to manufacturing or timing issues. It provides a possible treatment option when remaking the therapy isn't an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your doctor has prescribed a treatment called Orca-T for you.
- The final batch of Orca-T made for you is not perfect (doesn't meet commercial standards or is expired).
- Both your doctor and the company agree the batch is still okay to use.
- It is not safe or practical to make a new batch of Orca-T from your cells.
- Your doctor says you are healthy enough and stable to receive the Orca-T infusion.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy, orca-t, given after a lower-intensity chemo and radiation regimen for people with acute myeloid leukemia, mixed phenotype leukemia, or myelodysplastic syndrome. It aims to help patients who cannot tolerate full-intensity transplant conditioning.
This study tests a new way to give donor stem cells (called Orca-T) after a special type of chemotherapy and radiation. It is for people aged 60–75 with certain blood cancers that have not responded well to standard treatments.
This trial tests a new approach for people with advanced blood cancers who are getting a donor stem cell transplant. It aims to improve outcomes by using your own regulatory T cells along with the donor cells.
This Phase 1 trial studies Orca-Q to see if it is safe and works when added around the time of an allogeneic (donor) stem cell transplant for certain blood cancers. If you qualify, the study may offer a new option for managing the transplant immune response.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to fight blood cancers that have come back or stopped responding to standard treatments. The therapy uses your own immune cells, which are modified in a lab to better recognize and attack cancer cells.
This trial tests a new drug called ORB-021 for people with advanced solid tumors that have come back or not responded to other treatments. The goal is to see if ORB-021 is safe and how it affects the body.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.